| MeSH term | MeSH ID | Detail |
|---|---|---|
| Body Weight | D001835 | 333 associated lipids |
| Lung Neoplasms | D008175 | 171 associated lipids |
| Adenocarcinoma | D000230 | 166 associated lipids |
| Carcinoma, Hepatocellular | D006528 | 140 associated lipids |
| Hemolysis | D006461 | 131 associated lipids |
| Cell Transformation, Neoplastic | D002471 | 126 associated lipids |
| Insulin Resistance | D007333 | 99 associated lipids |
| Hypercholesterolemia | D006937 | 91 associated lipids |
| Diabetes Mellitus, Type 2 | D003924 | 87 associated lipids |
| Arteriosclerosis | D001161 | 86 associated lipids |
clarithromycin
clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.
Cross Reference
Introduction
To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with clarithromycin?
clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (63)
- J. Antimicrob. Chemother. (56)
- J. Clin. Microbiol. (39)
- Others (258)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with clarithromycin
PubChem Associated disorders and diseases
What pathways are associated with clarithromycin
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with clarithromycin?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
- J. Antimicrob. Chemother. (25)
- Antimicrob. Agents Chemother. (20)
- J. Clin. Microbiol. (9)
- Others (66)
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with clarithromycin?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with clarithromycin?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with clarithromycin?
Related references are published most in these journals:
- J. Antimicrob. Chemother. (20)
- Antimicrob. Agents Chemother. (17)
- J. Clin. Microbiol. (13)
- Others (57)
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with clarithromycin?
Mouse Model
Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).
Knock-out
Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).
Experimental Pneumococcal Meningitis
Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).
Related references are published most in these journals:
- Antimicrob. Agents Chemother. (2)
- J. Antimicrob. Chemother. (1)
- Clin. Diagn. Lab. Immunol. (1)
- Others (2)
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with clarithromycin
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Losurdo G et al. | Role of concomitant therapy for eradication: A technical note. | 2016 | World J. Gastroenterol. | pmid:27784977 |
| Huang JQ et al. | Do patients with non-ulcer dyspepsia respond differently to Helicobacter pylori eradication treatments from those with peptic ulcer disease? A systematic review. | 2005 | World J. Gastroenterol. | pmid:15884111 |
| Robles-Jara C et al. | Is a 7-day Helicobater pylori treatment enough for eradication and inactivation of gastric inflammatory activity? | 2008 | World J. Gastroenterol. | pmid:18473407 |
| Koussoulas V et al. | Evidence for the role of gastric mucosa at the secretion of soluble triggering receptor expressed on myeloid cells (strem-1) in peptic ulcer disease. | 2007 | World J. Gastroenterol. | pmid:17729416 |
| Gumurdulu Y et al. | Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey. | 2004 | World J. Gastroenterol. | pmid:14991935 |
| Mirbagheri SA et al. | Triple, standard quadruple and ampicillin-sulbactam-based quadruple therapies for H. pylori eradication: a comparative three-armed randomized clinical trial. | 2006 | World J. Gastroenterol. | pmid:16937475 |
| Ching SS et al. | Treatment of Helicobacter pylori in surgical practice: a randomised trial of triple versus quadruple therapy in a rural district general hospital. | 2008 | World J. Gastroenterol. | pmid:18609709 |
| Iannone A et al. | New fecal test for non-invasive detection: A diagnostic accuracy study. | 2018 | World J. Gastroenterol. | pmid:30038469 |
| Brennan DE et al. | Can bacterial virulence factors predict antibiotic resistant infection? | 2018 | World J. Gastroenterol. | pmid:29531461 |
| Buzás GM and Józan J | First-line eradication of H pylori infection in Europe: a meta-analysis based on congress abstracts, 1997-2004. | 2006 | World J. Gastroenterol. | pmid:16981260 |
| Wang B et al. | Standard triple therapy for Helicobacter pylori infection in China: a meta-analysis. | 2014 | World J. Gastroenterol. | pmid:25356059 |
| Ji F et al. | Effect of drug treatment on hyperplastic gastric polyps infected with Helicobacter pylori: a randomized, controlled trial. | 2006 | World J. Gastroenterol. | pmid:16586550 |
| Zhou Q et al. | Drug utilization of clarithromycin for gastrointestinal disease treatment. | 2008 | World J. Gastroenterol. | pmid:18932287 |
| Sereni G et al. | Efficacy of a therapeutic strategy for eradication of Helicobacter pylori infection. | 2012 | World J. Gastroenterol. | pmid:22969227 |
| Isomoto H et al. | Sofalcone, a mucoprotective agent, increases the cure rate of Helicobacter pylori infection when combined with rabeprazole, amoxicillin and clarithromycin. | 2005 | World J. Gastroenterol. | pmid:15786539 |
| Wang HH et al. | One-year follow-up study of Helicobacter pylori eradication rate with 13C-urea breath test after 3-d and 7-d rabeprazole-based triple therapy. | 2005 | World J. Gastroenterol. | pmid:15786549 |
| Bustamante-Rengifo JA et al. | Effect of treatment failure on the CagA EPIYA motif in strains from Colombian subjects. | 2017 | World J. Gastroenterol. | pmid:28373764 |
| Hwang JJ et al. | Efficacy of moxifloxacin-based sequential and hybrid therapy for first-line Helicobacter pylori eradication. | 2015 | World J. Gastroenterol. | pmid:26401089 |
| Gao XZ et al. | Standard triple, bismuth pectin quadruple and sequential therapies for Helicobacter pylori eradication. | 2010 | World J. Gastroenterol. | pmid:20818821 |
| Garza-González E et al. | A review of Helicobacter pylori diagnosis, treatment, and methods to detect eradication. | 2014 | World J. Gastroenterol. | pmid:24587620 |